Pacer Advisors Inc. lifted its holdings in NuVasive, Inc. (NASDAQ:NUVA) by 18.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,226 shares of the medical device company’s stock after buying an additional 982 shares during the period. Pacer Advisors Inc.’s holdings in NuVasive were worth $479,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of NUVA. OppenheimerFunds Inc. boosted its position in NuVasive by 55.8% during the first quarter. OppenheimerFunds Inc. now owns 1,210,999 shares of the medical device company’s stock valued at $90,438,000 after purchasing an additional 433,506 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of NuVasive by 70.8% in the first quarter. Victory Capital Management Inc. now owns 715,321 shares of the medical device company’s stock worth $53,420,000 after buying an additional 296,568 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of NuVasive in the first quarter worth about $20,724,000. Vanguard Group Inc. lifted its position in shares of NuVasive by 4.9% in the first quarter. Vanguard Group Inc. now owns 4,110,457 shares of the medical device company’s stock worth $306,969,000 after buying an additional 191,166 shares during the last quarter. Finally, Teachers Advisors LLC lifted its position in shares of NuVasive by 205.8% in the first quarter. Teachers Advisors LLC now owns 249,546 shares of the medical device company’s stock worth $18,636,000 after buying an additional 167,950 shares during the last quarter.
NuVasive, Inc. (NASDAQ NUVA) opened at 58.05 on Friday. NuVasive, Inc. has a one year low of $56.70 and a one year high of $81.68. The firm has a market capitalization of $2.95 billion, a P/E ratio of 91.42 and a beta of 1.08. The stock has a 50 day moving average price of $63.69 and a 200 day moving average price of $72.43.
NuVasive (NASDAQ:NUVA) last announced its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.02. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The business had revenue of $260.60 million during the quarter, compared to analysts’ expectations of $261.95 million. During the same quarter in the prior year, the company posted $0.40 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. On average, equities analysts predict that NuVasive, Inc. will post $2.00 EPS for the current fiscal year.
A number of research firms have recently commented on NUVA. Royal Bank Of Canada reiterated a “buy” rating and issued a $85.00 price objective on shares of NuVasive in a research note on Thursday, July 20th. BidaskClub upgraded NuVasive from a “hold” rating to a “buy” rating in a research note on Wednesday, July 19th. Jefferies Group LLC reiterated a “buy” rating and issued a $84.00 price objective on shares of NuVasive in a research note on Friday, June 30th. Canaccord Genuity reiterated a “buy” rating and issued a $80.00 price objective on shares of NuVasive in a research note on Friday, July 28th. Finally, Gabelli reiterated a “buy” rating on shares of NuVasive in a research note on Monday, July 31st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. NuVasive has an average rating of “Buy” and a consensus target price of $80.42.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by BBNS and is the property of of BBNS. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/pacer-advisors-inc-has-479000-position-in-nuvasive-inc-nuva/1599856.html.
In other news, EVP Peter Michael Leddy acquired 7,850 shares of NuVasive stock in a transaction on Tuesday, August 1st. The stock was acquired at an average cost of $63.88 per share, for a total transaction of $501,458.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Gregory T. Lucier acquired 2,000 shares of NuVasive stock in a transaction on Tuesday, August 29th. The shares were purchased at an average price of $61.52 per share, with a total value of $123,040.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 14,850 shares of company stock valued at $955,598. Corporate insiders own 1.20% of the company’s stock.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with our FREE daily email newsletter.